Compare ICUI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICUI | NAMS |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 1995 | N/A |
| Metric | ICUI | NAMS |
|---|---|---|
| Price | $146.10 | $32.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $182.25 | $47.33 |
| AVG Volume (30 Days) | 272.9K | ★ 666.3K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.62 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $2,231,262,000.00 | N/A |
| Revenue This Year | N/A | $38.17 |
| Revenue Next Year | $4.10 | $573.62 |
| P/E Ratio | $4,973.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $107.02 | $14.06 |
| 52 Week High | $160.29 | $42.00 |
| Indicator | ICUI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 42.43 |
| Support Level | $142.11 | $30.34 |
| Resistance Level | $151.64 | $37.43 |
| Average True Range (ATR) | 6.67 | 1.82 |
| MACD | -0.34 | -0.12 |
| Stochastic Oscillator | 28.86 | 5.46 |
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.